文献速递慢性肾脏病

成纤维细胞生长因子23与普通人群新发慢性肾脏病:PREVEND研究

Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

在PREVEND前瞻性人群队列中纳入5253例基线无慢性肾脏病(CKD)个体,中位随访7.5年。血浆C端FGF23每翻倍与新发CKD独立相关(全调整HR 1.25,95%CI 1.10-1.44,P=0.001),并与全因死亡风险升高相关(HR 1.30,95%CI 1.03-1.63,P=0.03)。

要点

  • 血浆FGF23每翻倍,新发CKD风险独立升高25%。
  • FGF23亦与全因死亡风险升高独立相关。
  • FGF23或可作为普通人群CKD风险的早期预警指标。

核心结论

  • 在普通人群中,较高的血浆FGF23水平与新发CKD及全因死亡风险升高独立相关。

研究设计与样本

  • 前瞻性人群队列PREVEND研究,纳入5253例基线无CKD的个体,采用多变量Cox回归分析。

主要发现

  • 中位基线FGF23为68(IQR 56-85)RU/mL,eGFR为95±13 mL/min/1.73 m2,UAE为7.8(IQR 5.8-11.5)mg/24 h。
  • 随访7.5(IQR 7.2-8.0)年,586例发生CKD,214例死亡。
  • FGF23每翻倍与新发CKD全调整HR 1.25(95%CI 1.10-1.44),P=0.001。
  • FGF23与新发eGFR<60 mL/min/1.73 m2独立相关,调整HR 1.28(95%CI 1.00-1.62),P=0.048;与UAE>30 mg/24 h独立相关,调整HR 1.24(95%CI 1.06-1.45),P=0.01。
  • FGF23与全因死亡风险升高相关,全调整HR 1.30(95%CI 1.03-1.63),P=0.03。

关键数值与推荐

  • 新发CKD定义为eGFR<60 mL/min/1.73 m2、24 h尿白蛋白排泄(UAE)>30 mg/24 h或两者兼有,或全因死亡的复合终点。

临床怎么用

  • 在普通人群风险评估中可关注血浆FGF23水平,用于识别CKD高危个体并加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset CKD in the general population. METHODS: We included 5253 individuals without CKD who participated in the Prevention of Renal and Vascular Endstage Disease study, a prospective, population-based cohort. Multi-variable Cox regression was used to study the association of plasma C-terminal FGF23 with new-onset CKD, defined as a combined endpoint of estimated glomerular filtration rate (eGFR) <60 mL/min/ 1.73 m2, urinary 24-h albumin excretion (UAE) >30 mg/24 h or both, or with all-cause mortality. RESULTS: The median baseline FGF23 was 68 [interquartile range (IQR) 56-85] RU/mL, eGFR was 95 ± 13 mL/min/1.73 m2 and UAE was 7.8 (IQR 5.8-11.5) mg/24 h. After follow-up of 7.5 (IQR 7.2-8.0) years, 586 participants developed CKD and 214 participants died. A higher FGF23 level was associated with new-onset CKD, independent of risk factors for kidney disease and parameters of bone and mineral homoeostasis {fully adjusted hazard ratio (HR) 1.25 [95% confidence interval (CI) 1.10-1.44] per doubling of FGF23; P = 0.001}. In secondary analyses, FGF23 was independently associated with new-onset eGFR <60 mL/min/1.73 m2 [adjusted HR 1.28 (95% CI 1.00-1.62); P = 0.048] or with UAE >30 mg/24 h [adjusted HR 1.24 (95% CI 1.06-1.45); P = 0.01] individually. A higher FGF23 level was also associated with an increased risk of all-cause mortality [fully adjusted HR 1.30 (95% CI 1.03-1.63); P = 0.03]. CONCLUSIONS: High FGF23 levels are associated with an increased risk of new-onset CKD and all-cause mortality in this prospective population-based cohort, independent of established CKD risk factors.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. De Jong MA, Eisenga MF, van Ballegooijen AJ, et al. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrol Dial Transplant. 2021. PMID: 32124925. doi:10.1093/ndt/gfz266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。